<DOC>
	<DOCNO>NCT01095250</DOCNO>
	<brief_summary>This study ass safety efficacy AIN457 adjunctive therapy treatment intermediate uveitis , posterior uveitis , panuveitis require systemic immunosuppression .</brief_summary>
	<brief_title>Safety Efficacy AIN457 Patients With Active Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Male female subject ≥18 year age . Where relevant , parent also sign informed consent accord local law regulation Patients diagnosis chronic noninfectious intermediate uveitis , posterior uveitis panuveitis least one eye Evidence active intermediate , posterior panuveitis ( grade ≥ 2+ vitreous haze without presence anterior chamber cell ) screen baseline least one eye Requirement follow immunosuppressive therapy treatment prevention uveitis : Prednisone equivalent ≥10 mg daily time within past 3 month . ≥1 periocular injection ≥1 intravitreal corticosteroid injection ( e.g . triamcinolone ) study eye within past 6 month ( last injection must give 6 week prior screen ) . Treatment either cyclosporine , tacrolimus , azathioprine , mycophenolate mofetil , mycophenolic acid , methotrexate time within past 3 month ( Patients treat chlorambucil cyclophosphamide within past 5 year ineligible study ) . Patients meet specified criterion immunosuppressive therapy eligible enrollment intolerant systemic immunosuppressive therapy determine study investigator . Patient must able understand communicate investigator comply requirement study must give write , sign date informed consent study assessment perform Ocular concomitant conditions/disease Patients receive may require prednisone ( equivalent ) ≥1.5 mg/kg/day treatment active uveitis Patients primary diagnosis Behcet 's disease , anterior uveitis intermediate uveitis , posterior uveitis panuveitis manifestation ( ) active intraocular inflammatory disease may spontaneously resolve characterize presence either anterior chamber cell vitritis ( vitreous cell haze ) white dot retinochoroidopathies ( i.e . Punctate inner choroidopathy ( PIC ) , acute zonal occult outer retinopathy ( AZOOR ) Patients infectious uveitis uveitis underlie diagnosis uncertain would reasonably include disease immunosuppression would contraindicate ( e.g . ocular lymphoma ) Ocular treatment Treatment intravitreal antiVEGF agent administer study eye within 3 month prior screen Treatment fluocinolone acetonide implant study eye within last 3 year , dexamethasone intravitreal implant investigational corticosteroid implant study eye within last 6 month . Intraocular surgery laser photocoagulation study eye within last 6 week prior screen except diagnostic vitreous aqueous tap smallgauge needle Ocular disease would interfere ocular evaluation ( e.g . corneal scarring , cataract , vitreous hemorrhage ) opinion investigator would complicate evaluation safety efficacy study treatment ( e.g . uncontrolled glaucoma , toxoplasma scar , macular scarring ) Current use likely need systemic medication know toxic lens , retina , optic nerve ( e.g. , deferoxamine , chloroquine , ethambutol , etc . ) Systemic condition treatment Any previous treatment AIN457 Any systemic biologic therapy ( e.g . interferon , infliximab , daclizumab , etanercept , adalimumab ) give intravenously subcutaneously within 3 month prior screen . No biologic therapy investigational study treatment allow course clinical trial Any prior treatment systemic alkylating agent ( cyclophosphamide , chlorambucil ) within past 5 year prior screen Treatment live liveattenuated vaccine ( include vaccine varicellazoster measles ) within 2 month prior screen . No treatment live liveattenuated vaccine allow course clinical trial Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Active uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
</DOC>